Antiplatelet Effects in Stroke-Patients

NCT02148939 | Completed

• 1 other identifier: Stroke
• Study Type: observational
• Target: 61
• Locations: 1 country
• Sites: 1

Brief Summary

Many patients suffer from acute and chronic pain. The incidence of chronic pain correlates with increased age. Most of patients rely on analgesic medication to control the pain. Dipyrone is an extensively used drug in Western and Eastern Europe as well as Central and South America, largely due to its favorable analgesic and antipyretic effects in conjunction with a low incidence of gastrointestinal complications when compared to other non-steroidal anti-inflammatory drugs (NSAIDs). Aspirin is the backbone of antiplatelet therapy in patients after ischemic stroke. However, it is known that there are substantial inter-individual response variabilities to antiplatelet medication. Furthermore, patients with impaired response to aspirin have a significant higher risk of recurrent cerebrovascular events. The investigators have recently shown that co-medication with aspirin and dipyrone in patients with coronary artery disease lead to insufficient antiplatelet effects of aspirin. The incidence of chronic pain is very high in patients with ischemic stroke. Therefore, in this study the investigators aim to examine, if co-medication of aspirin and dipyrone interaction also occurs in patients after ischemic stroke.

Conditions

Ischemic Stroke

Keywords

ischemic stroke; Antiplatelet Effects; aspirin; metamizole; dipyrone

Outcome Measures

Primary Outcomes (1)

• Laboratory response to aspirin therapy in metamizole co-medicated Stroke patients

  Baseline

Secondary Outcomes (1)

• Major adverse cardiac and cerebrovascular events (MACCE Events) during hospital stay

  participants are followed until discharge up to 4 weeks

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with ischemic stroke

You may qualify if:

• Age ≥ 18 years
• Patients with ischemic stroke and ASS-medication (80-320 mg/day) with/without analgesic comedication

You may not qualify if:

• Reanimation
• cardiogenic shock

Sponsors & Collaborators

• Heinrich-Heine University, Duesseldorf: lead

Study Sites (1)

Division of Cardiology, Pulmonary Disease and Vascular Medicine

Düsseldorf, 40225, Germany

Location

Related Publications (1)

• Dannenberg L, Erschoff V, Bonner F, Gliem M, Jander S, Levkau B, Kelm M, Hohlfeld T, Zeus T, Polzin A. Dipyrone comedication in aspirin treated stroke patients impairs outcome. Vascul Pharmacol. 2016 Dec;87:66-69. doi: 10.1016/j.vph.2016.06.003. Epub 2016 Jun 11.

  PMID: 27301652 DERIVED

Related Links

• Related Info

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Amin Polzin, MD

  Klinik für Kardiologie, Pneumologie und Angiologie, Universtiätsklinikum Düsseldorf

  PRINCIPAL INVESTIGATOR

• Tobias Zeus, MD

  Klinik für Kardiologie, Pneumologie und Angiologie, Universtiätsklinikum Düsseldorf

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Division of Cardiology, Pulmonary Diseases, Vascular Medicine

Study Record Dates

• First Submitted: May 16, 2014
• First Posted: May 29, 2014
• Study Start: May 1, 2014
• Primary Completion: February 1, 2015
• Study Completion: February 1, 2015
• Last Updated: March 10, 2015

Record last verified: 2015-03

Locations

DE (1)